Article
MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer
2018-02-28
Abstract excerpt
Docetaxel and cabazitaxel are taxane chemotherapy treatments for metastatic castration-resistant prostate cancer (CRPC). However, therapeutic resistance remains a major issue. MicroRNAs are short non-coding RNAs that can silence multiple genes, regulating several signalling pathways simultaneously. Therefore, synthetic microRNAs may have therapeutic potential in CRPC by regulating genes involved in taxane response...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 5626054c-8a59-58d1-95b5-82f6193fbe1a
- DOI
- 10.1101/273284
